Eris Lifesciences Limited has received a reaffirmation of its ‘IND AA’ long-term issuer and bank facility ratings from India Ratings and Research, maintaining a Stable outlook. The affirmation reflects the company’s sustained healthy operating performance, robust EBITDA growth, and successful integration of recent strategic acquisitions. The company continues to show strong competitive positioning in the Indian pharmaceutical market, particularly within chronic therapy segments, and maintains a prudent approach to managing its consolidated net leverage.
Consistent Operating Performance
Eris Lifesciences has demonstrated strong financial resilience with a sustained improvement in its operating profile. The company reported EBITDA of INR 8.5 billion for the nine months ended December 31, 2025 (9MFY26), compared to INR 7.6 billion in the same period the previous year. This growth is underpinned by increased product diversification, including an expanded portfolio in injectables and insulin, and a significantly larger manufacturing footprint compared to FY22.
Strategic Acquisitions and Market Position
The company’s growth strategy has been heavily driven by key strategic acquisitions between FY21 and FY25, including Oaknet Healthcare, various brands from Glenmark and Dr. Reddy’s Laboratories, and a 100% stake in Swiss Parenterals Limited. These investments have fast-tracked Eris’s entry into high-barrier segments like nephrology, immunotherapy, and oncology. As of March 31, 2026, 83% of the company’s portfolio is comprised of chronic and sub-chronic therapies, which provides high patient stickiness and long-term margin sustainability.
Financial Outlook and Leverage
Management has successfully improved the company’s credit metrics, with consolidated net leverage decreasing to 2.2x in FY25 from 3.9x in FY24. India Ratings expects this leverage to remain stable during FY26 and drop below 1.5x by FY27, assuming no significant new debt-funded acquisitions. The company maintains an adequate liquidity profile, supported by healthy EBITDA-to-cash flow conversion and internal accruals, which are expected to cover upcoming INR 2.75 billion term loan obligations in FY27.
Future Growth Drivers
With a field force of over 3,700 medical representatives and a focus on super-specialist doctors, Eris is well-positioned to capitalize on its expanded manufacturing capabilities. By transferring contract-manufactured portfolios to in-house facilities, the company aims to optimize costs and further improve its already robust consolidated EBITDA margins, which stood at 35.2% in FY25.
Source: BSE
